A study to investigate the relative bioavailability of 2 different formulations of AZD4144, the effect of food and omeprazole on the pharmacokinetics of AZD4144 in healthy participants

Exclusion Criteria

• 1. History of any clinically important disease or disorder that may put the participant at risk or influence study results.
• 2. History or presence of gastrointestinal, hepatic, or renal disease or any condition affecting drug absorption, distribution, metabolism, or excretion.
• 3. Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of randomization.
• 4. Active systemic bacterial, viral, or fungal infection within 14 days prior to dosing or presence of fever within 14 days prior to dosing.
• 5. Clinically significant serious active and chronic infections within 60 days prior to randomization.
• 6. Any history or evidence of tuberculosis (TB) (active or latent) using TB-QuantiFERON tests during screening.
• 7. Clinical signs and symptoms consistent with coronavirus disease 2019 (COVID-19).
• 8. Known history of primary immunodeficiency or an underlying condition that predisposes to infection.
• 9. Positive result for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV).
• 10. Plasma donation within one month of the screening visit or any blood donation/blood loss > 500 mL during the 3 months prior to the screening visit.
• 11. Participants who have previously received AZD4144.